This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kressner, U. Articles by Lindmark, G. Search for Related Content PubMed PubMed Citation Articles by Kressner, U. Articles by Lindmark, G. Social Bookmarking                            What's this?

Prognostic Value of p53 Genetic Changes in Colorectal Cancer

From the Departments of Surgery and Oncology, University Hospital, Uppsala; Pharmacia Biotech AB, Uppsala; and Department of Surgery, Umeå University Hospital, Umeå, Sweden.

Address reprint requests to Ulf Kressner, MD, PhD, Department of Surgery, Uddevalla sjukhus, 451 80 Uddevalla, Sweden; email ulf.kressner{at}nu.alvsborg.se

PURPOSE: To explore whether there is a linkage between different mutations in the p53 gene in primary colorectal cancer and the risk of death from colorectal cancer in a large group of patients with long follow-up. We also compared a complementary DNA-based sequencing method and an immunohistochemical (IHC) method for detecting p53 protein overexpression in colorectal cancer.

MATERIALS AND METHODS: The entire coding region of the p53 gene was sequenced in 191 frozen tumor samples collected from January 1988 to November 1992. RNA was extracted and synthesized to cDNA. p53 was amplified by the polymerase chain reaction, and the DO-7 monoclonal antibody was used in the IHC assessments.

RESULTS: Mutations were detected in 99 samples (52%) from 189 patients. There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03). There was no significant relationship between overexpression of p53 protein, as determined by IHC analysis, and cancer-specific survival.

CONCLUSION: Mutational analyses of the p53 gene, using cDNA sequencing in colorectal cancer, provide useful prognostic information. In addition, cDNA sequencing gives better prognostic information than IHC assessment of p53 protein overexpression.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin Ann. Onc., October 15, 2009; (2009) mdp383v1. [Abstract] [Full Text] [PDF]

				V. R. Katkoori, X. Jia, C. Shanmugam, W. Wan, S. Meleth, H. Bumpers, W. E. Grizzle, and U. Manne Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma Clin. Cancer Res., April 1, 2009; 15(7): 2406 - 2416. [Abstract] [Full Text] [PDF]

				G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up Anticancer Res, February 1, 2009; 29(2): 785 - 791. [Abstract] [Full Text] [PDF]

				P. M. Hoff Is There a Role for Routine p53 Testing in Colorectal Cancer? J. Clin. Oncol., October 20, 2005; 23(30): 7395 - 7396. [Full Text] [PDF]

				J. L. Westra, M. Schaapveld, H. Hollema, J. P. de Boer, M. M.J. Kraak, D. de Jong, A. ter Elst, N. H. Mulder, C. H.C.M. Buys, R. M.W. Hofstra, et al. Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients J. Clin. Oncol., August 20, 2005; 23(24): 5635 - 5643. [Abstract] [Full Text] [PDF]

				P. L. Paris, D. G. Albertson, J. C. Alers, A. Andaya, P. Carroll, J. Fridlyand, A. N. Jain, S. Kamkar, D. Kowbel, P.-J. Krijtenburg, et al. High-Resolution Analysis of Paraffin-Embedded and Formalin-Fixed Prostate Tumors Using Comparative Genomic Hybridization to Genomic Microarrays Am. J. Pathol., March 1, 2003; 162(3): 763 - 770. [Abstract] [Full Text] [PDF]

				C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]

				A. Russo, M. Migliavacca, I. Zanna, M. R. Valerio, M. A. Latteri, N. Grassi, G. Pantuso, S. Salerno, G. Dardanoni, I. Albanese, et al. p53 Mutations in L3-Loop Zinc-binding Domain, DNA-Ploidy, and S Phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer: A Prospective Study with a Five-Year Follow-Up Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1322 - 1331. [Abstract] [Full Text] [PDF]

				P. M. Calvert and H. Frucht The Genetics of Colorectal Cancer Ann Intern Med, October 1, 2002; 137(7): 603 - 612. [Abstract] [Full Text] [PDF]

				R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202. [Abstract] [Full Text] [PDF]

				C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743. [Abstract] [Full Text] [PDF]

				A. Forslund, C. Lonnroth, M. Andersson, H. Brevinge, and K. Lundholm Mutations and Allelic Loss of p53 in Primary Tumor DNA From Potentially Cured Patients With Colorectal Carcinoma J. Clin. Oncol., June 1, 2001; 19(11): 2829 - 2836. [Abstract] [Full Text] [PDF]

				H. Elsaleh, B. Powell, K. McCaul, F. Grieu, R. Grant, D. Joseph, and B. Iacopetta P53 Alteration and Microsatellite Instability Have Predictive Value for Survival Benefit from Chemotherapy in Stage III Colorectal Carcinoma Clin. Cancer Res., May 1, 2001; 7(5): 1343 - 1349. [Abstract] [Full Text]

				M. Inganas, S. Byding, A. Eckersten, S. Eriksson, T. Hultman, A. Jorsback, E. Lofman, F. Sabounchi, U. Kressner, G. Lindmark, et al. Enzymatic Mutation Detection in the P53 Gene Clin. Chem., October 1, 2000; 46(10): 1562 - 1573. [Abstract] [Full Text] [PDF]

				E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer Cancer Res., April 1, 2000; 60(8): 2155 - 2162. [Abstract] [Full Text]

				L. You, C.-T. Yang, and D. M. Jablons ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients Cancer Res., February 1, 2000; 60(4): 1009 - 1013. [Abstract] [Full Text]

				H. Zhang Evaluation of Four Antibodies in Detecting p53 Protein for Predicting Clinicopathological and Prognostic Significance in Colorectal Adenocarcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4126 - 4132. [Abstract] [Full Text] [PDF]